Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical risks of thrombolytic therapy.

R M Califf1, D F Fortin, A N Tenaglia

  • 1Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710.

The American Journal of Cardiology
|January 3, 1992
PubMed
Summary

Understanding clinical risks of intravenous thrombolytic therapy is crucial for patient selection. Key risks include intracranial hemorrhage, systemic bleeding, and immunologic reactions, with myocardial rupture a growing concern.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antibodies to tissue transglutaminase: an immune link between the gut, the coronaries and the myocardium?

Journal of internal medicine·2007
Same author

Production of plasminogen activator inhibitor-1 (PAI-1) by endothelial cells: differential responses to calcitriol and paricalcitol.

Journal of thrombosis and haemostasis : JTH·2004
Same author

Selective serotonin reuptake inhibitors yield additional antiplatelet protection in patients with congestive heart failure treated with antecedent aspirin.

European journal of heart failure·2003
Same author

Matrix Gla protein (MGP) and bone morphogenetic protein-2 in aortic calcified lesions of aging rats.

Journal of thrombosis and haemostasis : JTH·2003
Same author

Synthesis of RGD analogs as potential vectors for targeted drug delivery.

Bioorganic chemistry·2002
Same author

A molecular mechanism for genetic warfarin resistance in the rat.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2001

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Intravenous thrombolytic therapy is vital for treating acute cardiovascular events.
  • Appropriate patient selection requires a thorough understanding of potential clinical risks.

Purpose of the Study:

  • To classify and describe the major clinical risks associated with intravenous thrombolytic therapy.
  • To provide a framework for evaluating the risk-benefit profile in patient selection.

Main Methods:

  • Review and classification of major complications from existing literature and clinical trials.
  • Identification of risk factors associated with specific complications.

Main Results:

  • Major risks include intracranial hemorrhage (0.2-1%), systemic hemorrhage, immunologic complications (with streptokinase/anistreplase), hypotension, and myocardial rupture.

Related Experiment Videos

  • Thromboembolic complications and "reperfusion arrhythmias" are rare or clinically insignificant.
  • Risk factors for bleeding are being identified through large trials like the Global Utilization of t-PA and Streptokinase (GUSTO) Trial.

    • Conclusions:

    • A comprehensive understanding of thrombolytic therapy risks is essential for safe and effective patient management.
    • Patients at highest risk for complications may also derive the greatest benefit from treatment.
    • Ongoing trials are refining our understanding of bleeding risks to aid clinical decision-making.